MTOR and malignant colon neoplasm: To further investigate the involvement of PI3K/Akt/mTOR signaling in the AST-induced anti-angiogenic effects against colon cancer, HCT 116 cells were treated with PI3K inhibitor LY294002 (50 μM), Akt inhibitor (10 μM) or mTOR inhibitor rapamycin (50 nM), respectively.